|
Thu, 10/30/2025 - 12:58 |
Longitudinal Study: Inhaled Cannabis Is Safe and Effective for Treating Refractory Diabetic Neuropathy |
NORML |
|
Fri, 10/17/2025 - 12:24 |
Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc. |
Boston Scientific |
|
Tue, 10/14/2025 - 19:03 |
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit |
Lexicon Pharmac... |
|
Wed, 10/08/2025 - 16:27 |
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain |
Lexicon Pharmac... |
|
Fri, 09/19/2025 - 03:28 |
Study: Cannabis Use Promotes Improvements in Patients With Chemotherapy-Induced Peripheral Neuropathy |
NORML |
|
Fri, 09/12/2025 - 17:30 |
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings |
Lexicon Pharmac... |
|
Thu, 09/04/2025 - 18:03 |
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 |
Lexicon Pharmac... |
|
Fri, 07/18/2025 - 20:19 |
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) |
Lexicon Pharmac... |
|
Sun, 03/02/2025 - 22:03 |
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain |
Lexicon Pharmac... |
|
Fri, 01/31/2025 - 13:57 |
FDA approval of non-opioid pain drug is a major breakthrough, expert says |
Northwestern Un... |
|
Thu, 01/23/2025 - 12:51 |
Study: Patients Report Significant Reductions in Pain Following Cannabis Use |
NORML |
|
Tue, 01/21/2025 - 16:38 |
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain |
Lexicon Pharmac... |
|
Tue, 01/21/2025 - 13:53 |
Cannabinoids offer new hope for safe and effective pain relief |
YaleUniversity |
|
Thu, 12/19/2024 - 21:50 |
Review: Clinical Trials Demonstrate Effectiveness of Cannabinoids for Managing Peripheral Neuropathy |
NORML |
|
Thu, 08/22/2024 - 03:46 |
Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat Pain |
Tris Pharma |
|
Tue, 08/13/2024 - 11:48 |
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio |
Lexicon Pharmac... |
|
Wed, 06/19/2024 - 10:45 |
Data From Lexicons RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association |
Lexicon Pharmac... |
|
Fri, 06/14/2024 - 12:03 |
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association |
Lexicon Pharmac... |
|
Thu, 06/13/2024 - 18:22 |
Preclinical Study: Cannabis Terpenes Produce Potent Analgesic Effects |
NORML |
|
Wed, 12/21/2022 - 14:38 |
Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia |
Lexicon Pharmac... |
|
Mon, 11/14/2022 - 13:54 |
Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results from the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit |
Lexicon Pharmac... |
|
Mon, 10/24/2022 - 14:09 |
Lexicon Pharmaceuticals Announces Oral Presentations Relating to Its LX9211 Neuropathic Pain Program at the World Brain Disorders and Neuroscience Summit 2022 |
Lexicon Pharmac... |
|
Sun, 12/12/2021 - 21:40 |
Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain |
Trevena |
|
Tue, 10/26/2021 - 04:18 |
Neuro Vigor and the University of Western Australia announce drug development collaboration agreement |
Purdue |
|
Tue, 09/07/2021 - 20:20 |
HJF Fellowship Award Winners for 2021 |
HJF |
